The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised




About Siamab Therapeutics

Siamab Therapeutics is a biopharmaceutical company developing cancer immunotherapies. Siamab has developed a platform of technologies that enable the discovery and development of therapeutic antibodies that bind to a class of carbohydrate antigens present in cancer cells.

Siamab Therapeutics Headquarter Location

90 Bridge Street Suite 100

Newton, Massachusetts, 02458,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Siamab Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Siamab Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

838 items

Siamab Therapeutics Patents

Siamab Therapeutics has filed 13 patents.

The 3 most popular patent topics include:

  • Cancer treatments
  • Carcinogenesis
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immunology, Monoclonal antibodies, Immune system, Transcription factors


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immunology, Monoclonal antibodies, Immune system, Transcription factors



Latest Siamab Therapeutics News

Maine investors profit from investment in Mass. biotech company

Mar 26, 2021

biotech company by The Bangor Angels Fund and several members of the Maine Angels have received a return on their investments in Siamab Therapeutics, a Massachusetts-based biopharmaceutical company developing novel cancer therapeutics. In mid 2019, Siamab Therapeutics announced it entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company. Shareholders in the company have received a series of milestone payments from the agreement based on results of the company’s Phase I clinical trial . Full details on the transaction have not been disclosed. “Siamab developed a unique platform to target sugar receptors on tumor cells, in contrast with traditional protein-based targets,” said Fritz Oldenburg, a former physician who helped launch the Bangor Angels group in 2014. “Their recent studies suggest that the molecules are particularly effective against uterine, GI, and kidney cancers.” Ten Maine Angel members and the Bangor Angel Fund invested approximately $750,000 in Siamab Therapeutics since 2013, according to Ralph Nodine, chair of Maine Angels. (Whereas the Maine Angels invest as individuals, though share their expertise and due diligence, the Bangor Angels pool their capital into an investment fund that does the investing.) The Maine investors are anticipating additional payouts based on the future success of a Phase II clinical trial, according to Nodine. While the majority of investments by Maine Angel members and Bangor Angel Fund are in Maine-based companies, the groups also use the expertise of its members to consider investments in certain out-of-state companies in other industries, such as medical technology. Maine Startups Insider recently reported that the Maine Angels group, which consists of high-net-worth individuals who pool their resources to invest in and mentor early-stage companies, invested $3.3 million in 19 companies in 2020, and grew its membership by more than 40%. Share this:

  • Where is Siamab Therapeutics's headquarters?

    Siamab Therapeutics's headquarters is located at 90 Bridge Street, Newton.

  • What is Siamab Therapeutics's latest funding round?

    Siamab Therapeutics's latest funding round is Acquired.

  • How much did Siamab Therapeutics raise?

    Siamab Therapeutics raised a total of $10.49M.

  • Who are the investors of Siamab Therapeutics?

    Investors of Siamab Therapeutics include Boston Harbor Angels, JLabs, Launchpad Venture Group, Maine Angels, Mass Medical Angels and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.